Review



apg 115 treatment  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress apg 115 treatment
    <t>APG-115</t> <t>exhibits</t> therapeutic effects on TC both in vitro and in vivo. (A) CCK-8 assay demonstrating the relative cell viability of TPC-1 and B-CPAP cells at different concentrations of APG-115. (B) Cell scratch assay of B-CPAP and TPC-1 cells treated with APG-115 at 0 and 24 h. Scar bar = 100 μM. (C) Photograph of the tumors from the control and APG-115 treatment groups. (D,E) Tumor volume and weight of the mice from the control and APG-115 treatment groups. * p < 0.05 versus control group. Data are expressed as mean ± SEM, n = 5.
    Apg 115 Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apg 115 treatment/product/MedChemExpress
    Average 93 stars, based on 6 article reviews
    apg 115 treatment - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer"

    Article Title: APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer

    Journal: ACS Omega

    doi: 10.1021/acsomega.5c04710

    APG-115 exhibits therapeutic effects on TC both in vitro and in vivo. (A) CCK-8 assay demonstrating the relative cell viability of TPC-1 and B-CPAP cells at different concentrations of APG-115. (B) Cell scratch assay of B-CPAP and TPC-1 cells treated with APG-115 at 0 and 24 h. Scar bar = 100 μM. (C) Photograph of the tumors from the control and APG-115 treatment groups. (D,E) Tumor volume and weight of the mice from the control and APG-115 treatment groups. * p < 0.05 versus control group. Data are expressed as mean ± SEM, n = 5.
    Figure Legend Snippet: APG-115 exhibits therapeutic effects on TC both in vitro and in vivo. (A) CCK-8 assay demonstrating the relative cell viability of TPC-1 and B-CPAP cells at different concentrations of APG-115. (B) Cell scratch assay of B-CPAP and TPC-1 cells treated with APG-115 at 0 and 24 h. Scar bar = 100 μM. (C) Photograph of the tumors from the control and APG-115 treatment groups. (D,E) Tumor volume and weight of the mice from the control and APG-115 treatment groups. * p < 0.05 versus control group. Data are expressed as mean ± SEM, n = 5.

    Techniques Used: In Vitro, In Vivo, CCK-8 Assay, Wound Healing Assay, Control

    APG-115 inhibits the growth of TC patient-derived organoids. (A) Images of TC patient-derived organoids after APG-115 treatment. Scale bar = 100 μM. (B) Concentration–response viability curves of organoids following APG-115 treatment for 5 days. (C) IC 50 values of TC-derived organoids in APG-115 treatment.
    Figure Legend Snippet: APG-115 inhibits the growth of TC patient-derived organoids. (A) Images of TC patient-derived organoids after APG-115 treatment. Scale bar = 100 μM. (B) Concentration–response viability curves of organoids following APG-115 treatment for 5 days. (C) IC 50 values of TC-derived organoids in APG-115 treatment.

    Techniques Used: Derivative Assay, Concentration Assay

    APG-115 treatment upregulates the expression levels of PD-L1, p53, and MDM2 in TC cells. (A) WB assay detected the proteins of PD-L1, p53, and MDM2 in TPC-1 and B-CPAP cells after treatment with APG-115 at 0.125, 0.25, 0.5, 1.0, and 2.0 μM. (B)­Relative expression levels of MDM2, PD-L1, and p53 proteins in BCPAP and TPC-1 cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (C) Immunohistochemical staining of the PD-L1 and MDM2 from the tissues of control and APG-115-treated groups. Scale bar = 20 μM. (D) Percentage of immunohistochemically positive area of MDM2 and PD-L1 in mouse tissues from control and APG-115-treated groups. * p < 0.05, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (E) Flow cytometry analysis demonstrating the PD-L1 expression levels in TPC-1 cells from control and APG-115 treatment groups. (F) Correlation analysis of PD-L1 expression level and the p53 pathway in TC.
    Figure Legend Snippet: APG-115 treatment upregulates the expression levels of PD-L1, p53, and MDM2 in TC cells. (A) WB assay detected the proteins of PD-L1, p53, and MDM2 in TPC-1 and B-CPAP cells after treatment with APG-115 at 0.125, 0.25, 0.5, 1.0, and 2.0 μM. (B)­Relative expression levels of MDM2, PD-L1, and p53 proteins in BCPAP and TPC-1 cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (C) Immunohistochemical staining of the PD-L1 and MDM2 from the tissues of control and APG-115-treated groups. Scale bar = 20 μM. (D) Percentage of immunohistochemically positive area of MDM2 and PD-L1 in mouse tissues from control and APG-115-treated groups. * p < 0.05, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (E) Flow cytometry analysis demonstrating the PD-L1 expression levels in TPC-1 cells from control and APG-115 treatment groups. (F) Correlation analysis of PD-L1 expression level and the p53 pathway in TC.

    Techniques Used: Expressing, Control, Immunohistochemical staining, Staining, Flow Cytometry

    (A) Images of TPC-1 and B-CPAP cells after APG-115 treatment at different concentrations detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (B,C) WB assay demonstrated the proteins of SLC7A11 and GPX4 levels following APG-115 treatment in TPC-1 and B-CPAP cells; Relative expression levels of SLC7A11 and GPX4 proteins in BCPAP and TPC-1 cells following APG-115 treatment. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (D) Images of TPC-1 and B-CPAP cells in control, APG-115, FER-1, and combined treatment groups were detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (E) WB assay and the relative expression levels of SLC7A11 and PD-L1 proteins in control, APG-115, FER-1, and combined treatment groups, both in TPC-1 and B-CPAP cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001. Data are expressed as mean ± SEM, n = 3.
    Figure Legend Snippet: (A) Images of TPC-1 and B-CPAP cells after APG-115 treatment at different concentrations detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (B,C) WB assay demonstrated the proteins of SLC7A11 and GPX4 levels following APG-115 treatment in TPC-1 and B-CPAP cells; Relative expression levels of SLC7A11 and GPX4 proteins in BCPAP and TPC-1 cells following APG-115 treatment. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (D) Images of TPC-1 and B-CPAP cells in control, APG-115, FER-1, and combined treatment groups were detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (E) WB assay and the relative expression levels of SLC7A11 and PD-L1 proteins in control, APG-115, FER-1, and combined treatment groups, both in TPC-1 and B-CPAP cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001. Data are expressed as mean ± SEM, n = 3.

    Techniques Used: Expressing, Control



    Similar Products

    apg 115 treatment  (MedChemExpress)
    93
    MedChemExpress apg 115 treatment
    <t>APG-115</t> <t>exhibits</t> therapeutic effects on TC both in vitro and in vivo. (A) CCK-8 assay demonstrating the relative cell viability of TPC-1 and B-CPAP cells at different concentrations of APG-115. (B) Cell scratch assay of B-CPAP and TPC-1 cells treated with APG-115 at 0 and 24 h. Scar bar = 100 μM. (C) Photograph of the tumors from the control and APG-115 treatment groups. (D,E) Tumor volume and weight of the mice from the control and APG-115 treatment groups. * p < 0.05 versus control group. Data are expressed as mean ± SEM, n = 5.
    Apg 115 Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apg 115 treatment/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    apg 115 treatment - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    APG-115 exhibits therapeutic effects on TC both in vitro and in vivo. (A) CCK-8 assay demonstrating the relative cell viability of TPC-1 and B-CPAP cells at different concentrations of APG-115. (B) Cell scratch assay of B-CPAP and TPC-1 cells treated with APG-115 at 0 and 24 h. Scar bar = 100 μM. (C) Photograph of the tumors from the control and APG-115 treatment groups. (D,E) Tumor volume and weight of the mice from the control and APG-115 treatment groups. * p < 0.05 versus control group. Data are expressed as mean ± SEM, n = 5.

    Journal: ACS Omega

    Article Title: APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer

    doi: 10.1021/acsomega.5c04710

    Figure Lengend Snippet: APG-115 exhibits therapeutic effects on TC both in vitro and in vivo. (A) CCK-8 assay demonstrating the relative cell viability of TPC-1 and B-CPAP cells at different concentrations of APG-115. (B) Cell scratch assay of B-CPAP and TPC-1 cells treated with APG-115 at 0 and 24 h. Scar bar = 100 μM. (C) Photograph of the tumors from the control and APG-115 treatment groups. (D,E) Tumor volume and weight of the mice from the control and APG-115 treatment groups. * p < 0.05 versus control group. Data are expressed as mean ± SEM, n = 5.

    Article Snippet: We measured the cell viability of TC cell lines B-CPAP and TPC-1 following APG-115 treatment using a CCK-8 kit (HY-K0301, MCE).

    Techniques: In Vitro, In Vivo, CCK-8 Assay, Wound Healing Assay, Control

    APG-115 inhibits the growth of TC patient-derived organoids. (A) Images of TC patient-derived organoids after APG-115 treatment. Scale bar = 100 μM. (B) Concentration–response viability curves of organoids following APG-115 treatment for 5 days. (C) IC 50 values of TC-derived organoids in APG-115 treatment.

    Journal: ACS Omega

    Article Title: APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer

    doi: 10.1021/acsomega.5c04710

    Figure Lengend Snippet: APG-115 inhibits the growth of TC patient-derived organoids. (A) Images of TC patient-derived organoids after APG-115 treatment. Scale bar = 100 μM. (B) Concentration–response viability curves of organoids following APG-115 treatment for 5 days. (C) IC 50 values of TC-derived organoids in APG-115 treatment.

    Article Snippet: We measured the cell viability of TC cell lines B-CPAP and TPC-1 following APG-115 treatment using a CCK-8 kit (HY-K0301, MCE).

    Techniques: Derivative Assay, Concentration Assay

    APG-115 treatment upregulates the expression levels of PD-L1, p53, and MDM2 in TC cells. (A) WB assay detected the proteins of PD-L1, p53, and MDM2 in TPC-1 and B-CPAP cells after treatment with APG-115 at 0.125, 0.25, 0.5, 1.0, and 2.0 μM. (B)­Relative expression levels of MDM2, PD-L1, and p53 proteins in BCPAP and TPC-1 cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (C) Immunohistochemical staining of the PD-L1 and MDM2 from the tissues of control and APG-115-treated groups. Scale bar = 20 μM. (D) Percentage of immunohistochemically positive area of MDM2 and PD-L1 in mouse tissues from control and APG-115-treated groups. * p < 0.05, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (E) Flow cytometry analysis demonstrating the PD-L1 expression levels in TPC-1 cells from control and APG-115 treatment groups. (F) Correlation analysis of PD-L1 expression level and the p53 pathway in TC.

    Journal: ACS Omega

    Article Title: APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer

    doi: 10.1021/acsomega.5c04710

    Figure Lengend Snippet: APG-115 treatment upregulates the expression levels of PD-L1, p53, and MDM2 in TC cells. (A) WB assay detected the proteins of PD-L1, p53, and MDM2 in TPC-1 and B-CPAP cells after treatment with APG-115 at 0.125, 0.25, 0.5, 1.0, and 2.0 μM. (B)­Relative expression levels of MDM2, PD-L1, and p53 proteins in BCPAP and TPC-1 cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (C) Immunohistochemical staining of the PD-L1 and MDM2 from the tissues of control and APG-115-treated groups. Scale bar = 20 μM. (D) Percentage of immunohistochemically positive area of MDM2 and PD-L1 in mouse tissues from control and APG-115-treated groups. * p < 0.05, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (E) Flow cytometry analysis demonstrating the PD-L1 expression levels in TPC-1 cells from control and APG-115 treatment groups. (F) Correlation analysis of PD-L1 expression level and the p53 pathway in TC.

    Article Snippet: We measured the cell viability of TC cell lines B-CPAP and TPC-1 following APG-115 treatment using a CCK-8 kit (HY-K0301, MCE).

    Techniques: Expressing, Control, Immunohistochemical staining, Staining, Flow Cytometry

    (A) Images of TPC-1 and B-CPAP cells after APG-115 treatment at different concentrations detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (B,C) WB assay demonstrated the proteins of SLC7A11 and GPX4 levels following APG-115 treatment in TPC-1 and B-CPAP cells; Relative expression levels of SLC7A11 and GPX4 proteins in BCPAP and TPC-1 cells following APG-115 treatment. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (D) Images of TPC-1 and B-CPAP cells in control, APG-115, FER-1, and combined treatment groups were detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (E) WB assay and the relative expression levels of SLC7A11 and PD-L1 proteins in control, APG-115, FER-1, and combined treatment groups, both in TPC-1 and B-CPAP cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001. Data are expressed as mean ± SEM, n = 3.

    Journal: ACS Omega

    Article Title: APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer

    doi: 10.1021/acsomega.5c04710

    Figure Lengend Snippet: (A) Images of TPC-1 and B-CPAP cells after APG-115 treatment at different concentrations detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (B,C) WB assay demonstrated the proteins of SLC7A11 and GPX4 levels following APG-115 treatment in TPC-1 and B-CPAP cells; Relative expression levels of SLC7A11 and GPX4 proteins in BCPAP and TPC-1 cells following APG-115 treatment. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (D) Images of TPC-1 and B-CPAP cells in control, APG-115, FER-1, and combined treatment groups were detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (E) WB assay and the relative expression levels of SLC7A11 and PD-L1 proteins in control, APG-115, FER-1, and combined treatment groups, both in TPC-1 and B-CPAP cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001. Data are expressed as mean ± SEM, n = 3.

    Article Snippet: We measured the cell viability of TC cell lines B-CPAP and TPC-1 following APG-115 treatment using a CCK-8 kit (HY-K0301, MCE).

    Techniques: Expressing, Control